Imagion Biosystems is pleased to announce that Monash Health has been established as the first clinical site and is ready to commence enrolment of patients for the MagSense® HER2 breast cancer Phase I first-in-human study.
Read the announcement.
Home » First In-human Study Update: Study Open for Enrolment
Imagion Biosystems is pleased to announce that Monash Health has been established as the first clinical site and is ready to commence enrolment of patients for the MagSense® HER2 breast cancer Phase I first-in-human study.
Read the announcement.
Positive Final Results of Wayne State Collaboration Drives Completion of Phase 2 Study Protocol for IND Submission to FDA in December Key Highlights: MagSense® HER2
The Market Bull recently invited Imagion Biosystems’ Ward Detwiler and Wayne State University’s Dr. Mark Haacke on the podcast to discuss how molecular MRI and
We are excited to announce that Imagion Biosystems (ASX: IBX) will be attending two premier medical conferences this fall: the Radiological Society of North
We’re on a mission to make cancer more detectable.
